Q1 2022 13F Holders as of 3/31/2022
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
112M
-
Number of holders
-
287
-
Total 13F shares, excl. options
-
81.1M
-
Shares change
-
+2.8M
-
Total reported value, excl. options
-
$6.72B
-
Value change
-
+$238M
-
Put/Call ratio
-
1.61
-
Number of buys
-
130
-
Number of sells
-
-150
-
Price
-
$82.85
Significant Holders of NovoCure Ltd - Common Stock (NVCR) as of Q1 2022
370 filings reported holding NVCR - NovoCure Ltd - Common Stock as of Q1 2022.
NovoCure Ltd - Common Stock (NVCR) has 287 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 81.1M shares
of 112M outstanding shares and own 72.4% of the company stock.
Largest 10 shareholders include Capital World Investors (12.7M shares), Capital International Investors (11.3M shares), FMR LLC (10.7M shares), BAILLIE GIFFORD & CO (9.34M shares), VANGUARD GROUP INC (8M shares), BlackRock Inc. (6.73M shares), STATE STREET CORP (2.5M shares), PRICE T ROWE ASSOCIATES INC /MD/ (2.11M shares), CREDIT SUISSE AG/ (1.36M shares), and GEODE CAPITAL MANAGEMENT, LLC (1.24M shares).
This table shows the top 287 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.